A slow start to the new millennium. Zyvox, Concerta and Mifeprex headline the year.
Cornell
S
S
D000021:Abortifacient Agents, Steroidal / Q000494:pharmacology / Q000600:supply & distribution; D000081:Acetamides / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D004347:Drug Interactions; D006801:Humans; D000069349:Linezolid; D008774:Methylphenidate / Q000494:pharmacology / Q000627:therapeutic use*; D015735:Mifepristone / Q000494:pharmacology / Q000600:supply & distribution; D023303:Oxazolidinones / Q000494:pharmacology / Q000627:therapeutic use*; D008517:Phytotherapy / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D000021:Abortifacient Agents, Steroidal; D000081:Acetamides; D000890:Anti-Infective Agents; D000697:Central Nervous System Stimulants; D023303:Oxazolidinones; D008774:Methylphenidate; D015735:Mifepristone; D000069349:Linezolid